Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypertension
  Free Subscription

Articles published in
Lancet
    November 2025
  1. FARRAR J, Frieden T
    WHO global report on hypertension 2025.
    Lancet. 2025;406:2318-2319.
    >> Share

    August 2025
  2. WANG N, Salam A, Pant R, Kumar A, et al
    Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
    Lancet. 2025;406:915-925.
    >> Share

  3. MCEVOY JW
    Optional hypertension: a new concept emerging from trials of intensive blood pressure control.
    Lancet. 2025 Aug 28:S0140-6736(25)01670-8. doi: 10.1016/S0140-6736(25)01670.
    >> Share

  4. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    >> Share

    May 2025
  5. FRIEDEN TR, Garg R, Moran AE, Whelton PK, et al
    Improved hypertension care requires measurement and management in health facilities, not mass screening.
    Lancet. 2025 May 7:S0140-6736(25)00561-6. doi: 10.1016/S0140-6736(25)00561.
    >> Share

    January 2025
  6. MCCARTHY CP, Bruno RM, Rahimi K, Touyz RM, et al
    Global and European landscape of major hypertension guidelines.
    Lancet. 2025 Jan 15:S0140-6736(24)02795-8. doi: 10.1016/S0140-6736(24)02795.
    >> Share

    October 2024
  7. RODGERS A, Salam A, Schutte AE, Cushman WC, et al
    Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical tria
    Lancet. 2024;404:1536-1546.
    >> Share

  8. ANTONOPOULOU M, Chliveros K
    A novel low-dose triple single-pill combination for hypertension.
    Lancet. 2024;404:1496-1498.
    >> Share

    August 2024

  9. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    >> Share

    July 2024
  10. WERNHART M, Wiesinger C, Windpessl M, Madl-Liebenberger L, et al
    A visual diagnosis of phaeochromocytoma crisis characterised by cyclic fluctuations of blood pressure: be on the look-out for rapid changes.
    Lancet. 2024;404:375-376.
    >> Share

  11. RAHIMI K
    Mounting evidence in favour of the lower, the better blood pressure paradigm.
    Lancet. 2024;404:216-217.
    >> Share

    June 2024
  12. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    >> Share

  13. HAYASHI SI, Kawano Y, Morishita R, Kusano KF, et al
    Time-lagged amelioration of vascular endothelial function in malignant hypertension: different organs improved at different rates.
    Lancet. 2024;403:2630-2631.
    >> Share

    May 2024
  14. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    >> Share

  15. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    >> Share

  16. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    >> Share

    March 2024
  17. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
    Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet. 2024;403:1061-1070.
    >> Share

  18. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
    Ambulatory blood pressure monitoring and mortality - Authors' reply.
    Lancet. 2024;403:812.
    >> Share

  19. LIU W, Ge W, Fan X, Du Y, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:811-812.
    >> Share

  20. MARTINEZ-GARCIA MA, Pengo MF, Parati G
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810-811.
    >> Share

  21. CHU WM, Ho HE, Wei JC
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810.
    >> Share

  22. LI SQ, Zhou JP, Wang Y, Li QY, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:809-810.
    >> Share

    November 2023
  23. JACKSON R, Rodgers A
    The ESH guidelines and missed prevention opportunities.
    Lancet. 2023;402:1729-1730.
    >> Share

    October 2023
  24. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    >> Share

  25. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    >> Share

  26. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016